Shopping Cart 0
Cart Subtotal
AED 0

AnaptysBio Inc (ANAB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

AnaptysBio Inc (AnaptysBio) is a clinical-stage biotechnology company that focuses on the development of antibody product candidates for the treatment of inflammatory, autoimmune and atopic diseases. The company develops its product candidates through its proprietary antibody discovery technology platform, somatic hypermutation (SHM). Its product candidates are being developed for the treatment of moderate-to-severe adult atopic dermatitis, food allergies and asthma, generalized pustular psoriasis and palmo-plantar pustular psoriasis and for the treatment of human autoimmune diseases. The company has partnership with AnaptysBio, TESARO and Celgene, to develop its product candidates. AnaptysBio is headquartered in San Diego, California, the US.

AnaptysBio Inc (ANAB)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

AnaptysBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

AnaptysBio Inc, Medical Devices Deals, 2012 to YTD 2018 10

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

AnaptysBio Raises USD40 Million in Series D Financing 12

AnaptysBio Raises USD 2 Million In Venture Financing 13

Partnerships 14

Momenta Pharma Enters into Co-Development Agreement with AnaptysBio for Antibody Discovery 14

AnaptysBio Enters Into Co-Development Agreement With Gilead Sciences For Antibody Discovery 15

AnaptysBio Enters Into Co-Development Agreement With Novartis 16

AnaptysBio Enters Into Co-Development Agreement With A Pharma Company 17

Licensing Agreements 18

Tesaro Amends Licensing Agreement With AnaptysBio 18

Equity Offering 20

AnaptysBio Raises USD239 Million in Public Offering of Shares 20

AnaptysBio Prices USD205.5 Million in Public Offering of Shares 22

AnaptysBio Raises USD0.9 Million in Private Placement of Shares up on Exercise of Warrants 23

AnaptysBio Raises USD1.8 Million in Private Placement of Shares up on Exercise of Warrants 24

AnaptysBio Raises USD86.3 Million in IPO 25

Asset Transactions 27

Momenta Pharma Exercises Option To Acquire Novel Antibodies Program from AnaptysBio 27

AnaptysBio Inc-Key Competitors 28

AnaptysBio Inc-Key Employees 29

AnaptysBio Inc-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 31

Financial Announcements 31

Aug 07, 2018: AnaptysBio announces second quarter 2018 financial results and provides pipeline updates 31

May 08, 2018: AnaptysBio Announces First Quarter 2018 Financial Results and Provides Pipeline Updates 34

Mar 05, 2018: AnaptysBio Reports Fourth Quarter and Full Year 2017 Financial Results 36

Nov 07, 2017: AnaptysBio Announces Third Quarter 2017 Financial Results and Provides Pipeline Updates 38

Aug 10, 2017: AnaptysBio Announces Second Quarter 2017 Financial Results and Provides Pipeline Updates 40

May 11, 2017: AnaptysBio Announces First Quarter 2017 Financial Results and Provides Pipeline Update 41

Mar 08, 2017: AnaptysBio Announces 2016 Operating Results and Pipeline Progress 42

Corporate Communications 44

Aug 24, 2017: AnaptysBio Announces Appointment of J. Anthony Ware, M.D. to Board of Directors 44

Jan 11, 2017: AnaptysBio Announces The Appointment Of Dominic Piscitelli As Chief Financial Officer 45

Clinical Trials 46

May 29, 2018: AnaptysBio Presents Updated ANB019 Clinical Data at the 2018 EAACI Congress 46

May 29, 2018: AnaptysBio Presents Updated ANB020 Clinical Data at the 2018 EAACI Congress 47

May 01, 2018: AnaptysBio Announces ANB019 Clinical Data Presentation at the 2018 EAACI Congress 49

May 01, 2018: AnaptysBio Announces ANB020 Clinical Data Presentation at the 2018 EAACI Congress 50

Mar 26, 2018: AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline Adult Peanut Allergy Patients 51

Feb 17, 2018: AnaptysBio Presents Updated Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting 53

Feb 07, 2018: AnaptysBio To Present Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting 54

Nov 06, 2017: AnaptysBio Reports Positive ANB019 Top-line Phase 1 Clinical Trial Results 55

Oct 10, 2017: AnaptysBio Reports Positive Topline Proof-of-Concept Data from Phase 2a Clinical Trial of ANB020 in Atopic Dermatitis 56

Apr 06, 2017: AnaptysBio Announces First-In-Human Dosing of ANB019 58

Mar 04, 2017: AnaptysBio Announces Data from Scientific Collaboration with the Benaroya Research Institute Presented at the AAAAI 2017 Annual Meeting 59

Feb 13, 2017: AnaptysBio to Present Data from ANB020 Program at Two Upcoming Medical Meetings 60

Appendix 61

Methodology 61

About GlobalData 61

Contact Us 61

Disclaimer 61


List Of Figure

List of Figures

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

AnaptysBio Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

AnaptysBio Inc, Pharmaceuticals & Healthcare, Key Facts 2

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

AnaptysBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

AnaptysBio Inc, Deals By Therapy Area, 2012 to YTD 2018 9

AnaptysBio Inc, Medical Devices Deals, 2012 to YTD 2018 10

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

AnaptysBio Raises USD40 Million in Series D Financing 12

AnaptysBio Raises USD 2 Million In Venture Financing 13

Momenta Pharma Enters into Co-Development Agreement with AnaptysBio for Antibody Discovery 14

AnaptysBio Enters Into Co-Development Agreement With Gilead Sciences For Antibody Discovery 15

AnaptysBio Enters Into Co-Development Agreement With Novartis 16

AnaptysBio Enters Into Co-Development Agreement With A Pharma Company 17

Tesaro Amends Licensing Agreement With AnaptysBio 18

AnaptysBio Raises USD239 Million in Public Offering of Shares 20

AnaptysBio Prices USD205.5 Million in Public Offering of Shares 22

AnaptysBio Raises USD0.9 Million in Private Placement of Shares up on Exercise of Warrants 23

AnaptysBio Raises USD1.8 Million in Private Placement of Shares up on Exercise of Warrants 24

AnaptysBio Raises USD86.3 Million in IPO 25

Momenta Pharma Exercises Option To Acquire Novel Antibodies Program from AnaptysBio 27

AnaptysBio Inc, Key Competitors 28

AnaptysBio Inc, Key Employees 29

AnaptysBio Inc, Subsidiaries 30

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

AnaptysBio Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

AnaptysBio Inc (AnaptysBio) is a clinical-stage biotechnology company that focuses on the development of antibody product candidates for the treatment of inflammatory, autoimmune and atopic diseases. The company develops its product candidates through its proprietary antibody discovery technology platform, somatic hypermutation (SHM). Its product candidates are being developed for the treatment of moderate-to-severe adult atopic dermatitis, food allergies and asthma, generalized pustular psoriasis and palmo-plantar pustular psoriasis and for the treatment of human autoimmune diseases. The company has partnership with AnaptysBio, TESARO and Celgene, to develop its product candidates. AnaptysBio is headquartered in San Diego, California, the US.

AnaptysBio Inc (ANAB)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

AnaptysBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

AnaptysBio Inc, Medical Devices Deals, 2012 to YTD 2018 10

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

AnaptysBio Raises USD40 Million in Series D Financing 12

AnaptysBio Raises USD 2 Million In Venture Financing 13

Partnerships 14

Momenta Pharma Enters into Co-Development Agreement with AnaptysBio for Antibody Discovery 14

AnaptysBio Enters Into Co-Development Agreement With Gilead Sciences For Antibody Discovery 15

AnaptysBio Enters Into Co-Development Agreement With Novartis 16

AnaptysBio Enters Into Co-Development Agreement With A Pharma Company 17

Licensing Agreements 18

Tesaro Amends Licensing Agreement With AnaptysBio 18

Equity Offering 20

AnaptysBio Raises USD239 Million in Public Offering of Shares 20

AnaptysBio Prices USD205.5 Million in Public Offering of Shares 22

AnaptysBio Raises USD0.9 Million in Private Placement of Shares up on Exercise of Warrants 23

AnaptysBio Raises USD1.8 Million in Private Placement of Shares up on Exercise of Warrants 24

AnaptysBio Raises USD86.3 Million in IPO 25

Asset Transactions 27

Momenta Pharma Exercises Option To Acquire Novel Antibodies Program from AnaptysBio 27

AnaptysBio Inc-Key Competitors 28

AnaptysBio Inc-Key Employees 29

AnaptysBio Inc-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 31

Financial Announcements 31

Aug 07, 2018: AnaptysBio announces second quarter 2018 financial results and provides pipeline updates 31

May 08, 2018: AnaptysBio Announces First Quarter 2018 Financial Results and Provides Pipeline Updates 34

Mar 05, 2018: AnaptysBio Reports Fourth Quarter and Full Year 2017 Financial Results 36

Nov 07, 2017: AnaptysBio Announces Third Quarter 2017 Financial Results and Provides Pipeline Updates 38

Aug 10, 2017: AnaptysBio Announces Second Quarter 2017 Financial Results and Provides Pipeline Updates 40

May 11, 2017: AnaptysBio Announces First Quarter 2017 Financial Results and Provides Pipeline Update 41

Mar 08, 2017: AnaptysBio Announces 2016 Operating Results and Pipeline Progress 42

Corporate Communications 44

Aug 24, 2017: AnaptysBio Announces Appointment of J. Anthony Ware, M.D. to Board of Directors 44

Jan 11, 2017: AnaptysBio Announces The Appointment Of Dominic Piscitelli As Chief Financial Officer 45

Clinical Trials 46

May 29, 2018: AnaptysBio Presents Updated ANB019 Clinical Data at the 2018 EAACI Congress 46

May 29, 2018: AnaptysBio Presents Updated ANB020 Clinical Data at the 2018 EAACI Congress 47

May 01, 2018: AnaptysBio Announces ANB019 Clinical Data Presentation at the 2018 EAACI Congress 49

May 01, 2018: AnaptysBio Announces ANB020 Clinical Data Presentation at the 2018 EAACI Congress 50

Mar 26, 2018: AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline Adult Peanut Allergy Patients 51

Feb 17, 2018: AnaptysBio Presents Updated Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting 53

Feb 07, 2018: AnaptysBio To Present Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting 54

Nov 06, 2017: AnaptysBio Reports Positive ANB019 Top-line Phase 1 Clinical Trial Results 55

Oct 10, 2017: AnaptysBio Reports Positive Topline Proof-of-Concept Data from Phase 2a Clinical Trial of ANB020 in Atopic Dermatitis 56

Apr 06, 2017: AnaptysBio Announces First-In-Human Dosing of ANB019 58

Mar 04, 2017: AnaptysBio Announces Data from Scientific Collaboration with the Benaroya Research Institute Presented at the AAAAI 2017 Annual Meeting 59

Feb 13, 2017: AnaptysBio to Present Data from ANB020 Program at Two Upcoming Medical Meetings 60

Appendix 61

Methodology 61

About GlobalData 61

Contact Us 61

Disclaimer 61


List Of Figure

List of Figures

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

AnaptysBio Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

AnaptysBio Inc, Pharmaceuticals & Healthcare, Key Facts 2

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

AnaptysBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

AnaptysBio Inc, Deals By Therapy Area, 2012 to YTD 2018 9

AnaptysBio Inc, Medical Devices Deals, 2012 to YTD 2018 10

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

AnaptysBio Raises USD40 Million in Series D Financing 12

AnaptysBio Raises USD 2 Million In Venture Financing 13

Momenta Pharma Enters into Co-Development Agreement with AnaptysBio for Antibody Discovery 14

AnaptysBio Enters Into Co-Development Agreement With Gilead Sciences For Antibody Discovery 15

AnaptysBio Enters Into Co-Development Agreement With Novartis 16

AnaptysBio Enters Into Co-Development Agreement With A Pharma Company 17

Tesaro Amends Licensing Agreement With AnaptysBio 18

AnaptysBio Raises USD239 Million in Public Offering of Shares 20

AnaptysBio Prices USD205.5 Million in Public Offering of Shares 22

AnaptysBio Raises USD0.9 Million in Private Placement of Shares up on Exercise of Warrants 23

AnaptysBio Raises USD1.8 Million in Private Placement of Shares up on Exercise of Warrants 24

AnaptysBio Raises USD86.3 Million in IPO 25

Momenta Pharma Exercises Option To Acquire Novel Antibodies Program from AnaptysBio 27

AnaptysBio Inc, Key Competitors 28

AnaptysBio Inc, Key Employees 29

AnaptysBio Inc, Subsidiaries 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

AnaptysBio Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.